Furthermore, in line with our findings, other studies showed that MRC1 is upregulated in AML compared to healthy volunteers and serves as a potential biomarker for AML, laying the groundwork for further development of targeted therapies aimed at suppressing excessive MRC1 expression in AML29,30. The gene discussed is MRC1; the disease is acute myeloid leukemia.